Establishing and evaluating FRAX(®) probability thresholds in Taiwan.

The Taiwanese FRAX® calculator was launched in 2010. However, cost-effectiveness thresholds for the prescription of antiosteoporosis medications were not established. This study aims to establish and evaluate FRAX®-based probability thresholds in Taiwan. Using previous data from Taiwan and literature, we determined cost-effectiveness thresholds for prevention of osteoporotic fractures by alendronate with a Markov model, as well as using two other translational approaches. Sensitivity analysis was applied using different alendronate prices. A clinical sample was used to test these Taiwan-specific thresholds by determining the percentages of high-risk patients who would be qualified for current National Health Insurance reimbursement. With the Markov model, the intervention threshold for hip fracture was 7% for women and 6% for men; for major osteoporotic fracture, it was 15% for women and 12.5% for men. Both translational approach models were cost effective only for certain age groups. However, if branded alendronate was reimbursed at 60% of the current price, they became cost effective in almost all age groups. This clinical screening study showed that the National Health Insurance Administration model identified the highest proportion (44%) of patients qualified for National Health Insurance reimbursements, followed by the Markov model (30%), and the United States model (22%). Three FRAX®-based models of alendronate use were established in Taiwan to help optimize treatment strategies. The government is encouraged to incorporate FRAX®-based approaches into the reimbursement policy for antiosteoporosis medicines.

Chan DC ，McCloskey EV ，Chang CB ，Lin KP ，Lim LC ，Tsai KS ，Yang RS ... -  《JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION》

Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.

Marques A ，Lourenço Ó ，Ortsäter G ，Borgström F ，Kanis JA ，da Silva JA ... -  《-》

Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.

Lippuner K ，Johansson H ，Borgström F ，Kanis JA ，Rizzoli R ... -  《-》

Cost-effective osteoporosis treatment thresholds in Greece.

Makras P ，Athanasakis K ，Boubouchairopoulou N ，Rizou S ，Anastasilakis AD ，Kyriopoulos J ，Lyritis GP ... -  《-》

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Ström O ，Jönsson B ，Kanis JA 《-》